Please login to the form below

paclitaxel

This page shows the latest paclitaxel news and features for those working in and with pharma, biotech and healthcare.

Another Tecentriq win for Roche as Avastin combo boosts survival

The 1, 200 patient trial compared PD-L1 inhibitor Tecentriq with VEGF inhibitor Avastin as a combination as well as each drug individually on top of carboplatin and paclitaxel chemotherapy.

Latest news

New data could put Roche’s Tecentriq first in squamous lung cancer

The phase III IMpower131 study showed that adding the PD-L1 inhibitor to standard first-line chemotherapy with carboplatin and Celgene’s Abraxane (nab-paclitaxel) in patients with advanced squamous ... the IMpower150 study which compared Tecentriq plus
MSD's Keytruda wins new bladder cancer indication in Europe

on investigator-choice chemotherapy (paclitaxel, docetaxel, vinflumime).
Celgene joins PD-1 race via partnership with BeiGene

BeiGene is also acquiring Celgene's commercial operations in Asia with the right to sell blood cancer therapies Revlimid (lenalidomide) and Vidaza (azacitidine) and Abraxane (albumin-bound paclitaxel) for pancreatic cancer -
Unhappy times continue at OncoMed with more disappointing results

with Celgene's Abraxane (albumin-bound paclitaxel) in previously-untreated patients with metastatic pancreatic cancer.
Keytruda, Opdivo narrow Tecentriq's lead in bladder cancer

The trial compared Keytruda to the investigator's choice of chemotherapy agents - paclitaxel, docetaxel or vinflunine - and showed that Merck's drug improved both progression-free survival (PFS) and overall survival.

More from news
Approximately 10 fully matching, plus 105 partially matching documents found.

Latest Intelligence

Pharma deals in May 2015

Sorrento (Igdrasol)/ NantPharma. Asset acquisition. Acquisition of Igdrasol including Cynviloq (paclitaxel nanoparticle).
The rise of chronic disease in BRIC markets

For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

BMS appoints oncology development head

Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer: Great salary and bebefits

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Account Manager – Med Comms – London: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Account Manager / Account Director: Great salary and bebefits

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Senior Account Manager or AD - Medical Communications: Salary TBC

Scientific Director: Great salary and bebefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Medical Writer: Great salary and benefits

Senior Programme Executive: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Senior Account Manager – Med Comms – Kent: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Editorial Director – Medical Education – Oxford: Negotiable

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Medical Writer - (London, Brighton or Copenhagen): Competitive

Subscribe to our email news alerts

PMHub

Add my company

3 Monkeys Zeno

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Latest intelligence

The Holy Grail of HCP Access: This is the data you need to gain access....
No incentive for a cure: The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....